JP2020510091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510091A5 JP2020510091A5 JP2019571788A JP2019571788A JP2020510091A5 JP 2020510091 A5 JP2020510091 A5 JP 2020510091A5 JP 2019571788 A JP2019571788 A JP 2019571788A JP 2019571788 A JP2019571788 A JP 2019571788A JP 2020510091 A5 JP2020510091 A5 JP 2020510091A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- solvate
- hydrate
- aryl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(*)(*)C(*)(*)C(*)(*)*C(N(*)*)=O Chemical compound *C(*)(*)C(*)(*)C(*)(*)*C(N(*)*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704327.4A GB201704327D0 (en) | 2017-03-17 | 2017-03-17 | Compounds |
| GB1704327.4 | 2017-03-17 | ||
| PCT/EP2018/056663 WO2018167269A1 (en) | 2017-03-17 | 2018-03-16 | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510091A JP2020510091A (ja) | 2020-04-02 |
| JP2020510091A5 true JP2020510091A5 (enExample) | 2021-04-30 |
| JP7211982B2 JP7211982B2 (ja) | 2023-01-24 |
Family
ID=58688233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571788A Active JP7211982B2 (ja) | 2017-03-17 | 2018-03-16 | Ｐｒｍｔ５媒介性障害の治療又は予防に有用な化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11485731B2 (enExample) |
| EP (1) | EP3596061B1 (enExample) |
| JP (1) | JP7211982B2 (enExample) |
| KR (1) | KR102616970B1 (enExample) |
| CN (1) | CN110650950B (enExample) |
| AU (2) | AU2018235139A1 (enExample) |
| CA (1) | CA3056724A1 (enExample) |
| GB (1) | GB201704327D0 (enExample) |
| IL (1) | IL269354B2 (enExample) |
| MX (1) | MX2019011061A (enExample) |
| NZ (1) | NZ757500A (enExample) |
| SG (1) | SG11201908598PA (enExample) |
| WO (1) | WO2018167269A1 (enExample) |
| ZA (1) | ZA201906269B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| US11464783B2 (en) | 2019-06-06 | 2022-10-11 | Aligos Therapeutics, Inc. | Heterocyclic compounds |
| CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
| ES3074517T3 (en) | 2019-12-17 | 2026-07-21 | Merck Sharp & Dohme Llc | 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease |
| EP4076459B1 (en) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| AU2021283568B2 (en) * | 2020-06-02 | 2023-12-14 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | 3,4-dihydroisoquinoline compound and use thereof |
| BR112022025037A2 (pt) | 2020-06-10 | 2023-02-14 | Aligos Therapeutics Inc | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus |
| CN115768769B (zh) * | 2020-06-30 | 2024-10-22 | 南京再明医药有限公司 | 四氢异喹啉类化合物及其用途 |
| KR102920599B1 (ko) | 2020-09-04 | 2026-01-29 | 이노웨이스톤 테라퓨틱스 리미티드 | 항종양 활성을 갖는 화합물 및 이의 용도 |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Ｔｙｋ２抑制劑及其用途 |
| CA3222626A1 (en) | 2021-05-13 | 2022-11-17 | Yunlong Song | Compound having anti-tumor activity and use thereof |
| GB202108383D0 (en) * | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12065428B2 (en) | 2021-09-17 | 2024-08-20 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| AU2022404488B2 (en) * | 2021-12-08 | 2026-04-02 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Salt of 3,4-dihydroisoquinoline compound and use thereof |
| WO2023125947A1 (zh) * | 2021-12-30 | 2023-07-06 | 江苏先声药业有限公司 | 四氢异喹啉类化合物的可药用盐、晶型及其用途 |
| WO2023131305A1 (zh) * | 2022-01-06 | 2023-07-13 | 江苏先声药业有限公司 | Prmt5抑制剂和抗癌治疗剂的组合 |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| AU2023303408A1 (en) | 2022-07-06 | 2024-12-19 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100764A2 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Methods of inhibiting prmt5 |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| WO2015200680A2 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3160466A4 (en) * | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US10494376B2 (en) | 2014-09-03 | 2019-12-03 | Ctxt Pty. Ltd. | Tetrahydroisoquinoline derived PRMT5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
-
2017
- 2017-03-17 GB GBGB1704327.4A patent/GB201704327D0/en not_active Ceased
-
2018
- 2018-03-16 CA CA3056724A patent/CA3056724A1/en active Pending
- 2018-03-16 AU AU2018235139A patent/AU2018235139A1/en not_active Abandoned
- 2018-03-16 EP EP18714178.3A patent/EP3596061B1/en active Active
- 2018-03-16 KR KR1020197030311A patent/KR102616970B1/ko active Active
- 2018-03-16 CN CN201880032332.4A patent/CN110650950B/zh active Active
- 2018-03-16 SG SG11201908598P patent/SG11201908598PA/en unknown
- 2018-03-16 NZ NZ757500A patent/NZ757500A/en unknown
- 2018-03-16 IL IL269354A patent/IL269354B2/en unknown
- 2018-03-16 JP JP2019571788A patent/JP7211982B2/ja active Active
- 2018-03-16 WO PCT/EP2018/056663 patent/WO2018167269A1/en not_active Ceased
- 2018-03-16 US US16/494,532 patent/US11485731B2/en active Active
- 2018-03-16 MX MX2019011061A patent/MX2019011061A/es unknown
-
2019
- 2019-09-23 ZA ZA2019/06269A patent/ZA201906269B/en unknown
-
2022
- 2022-04-11 AU AU2022202389A patent/AU2022202389B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529490A5 (enExample) | ||
| JP2019527203A5 (enExample) | ||
| JP2018522879A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| JP2018536634A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| JP2017508789A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2012522847A5 (enExample) | ||
| JP2019510810A5 (enExample) | ||
| JP2020527173A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2016537382A5 (enExample) | ||
| JP2021535112A5 (enExample) | ||
| JP2021508318A5 (enExample) | ||
| JP2023503962A5 (enExample) | ||
| RU2012109554A (ru) | Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией | |
| JP2020529994A5 (enExample) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2017508782A5 (enExample) | ||
| JP2017508816A5 (enExample) | ||
| RU2016134751A (ru) | Соединения |